Table 2.
The polymer NP-based drugs in clinical trials.
| Products | Drugs | Platform (NPs) | Status | Applications | Refs |
|---|---|---|---|---|---|
| Abraxane | Paclitaxel | Albumin | Approved | Lung, breast and pancreatic cancers | [69] |
| ABI-009 | Rapamycin | Albumin | Phase I/II | Solid tumors | [70] |
| ABI-008 | Docetaxel | Albumin | Phase I/II | Prostrate & breast cancers | [71] |
| BA-003 | Doxorubicin | Polymeric | Phase III | Hepatocellular cancer | [72] |
| BIND-014 | Docetaxel | PEG-PLGA polymeric | Phase I/II | Lung cancer | [73] |
| CALAA-01 | siRNA targeting | Cyclodextrin | Phase I | Solid tumors | [74] |
| DHAD-PBCA-NPs | Mitoxantrone | Polymeric | Phase II | Hepatocellular cancer | [75] |
| Docetaxel-PNP | Docetaxel | Polymeric | Phase I | Solid tumors | [76] |
| Nanotax | Paclitaxel | Polymeric | Phase I | Neoplasms | [77] |
| ProLindac | DACHPt | HPMA-polymeric | Phase II/III | Ovarian cancer | [78] |